Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Patients with relapsing-remitting multiple sclerosis should be offered disease-modifying therapies as part of their management. Recommended options include integrin antagonist therapy including natalizumab as well as anti-CD20 monoclonal antibodies like, ocrelizumab, rituximab, ofatumumab, ublituximab. These therapies reduce relapse rates and slow brain lesion accumulation. Disease-modifying therapies selection may depend on patient preferences, potential fetal harm, and specific drug risks, requiring continuous monitoring via tracking clinical relapses and new MRI brain lesions. Natalizumab carries a risk of progressive multifocal leukoencephalopathy, particularly in anti-JCV antibody-positive patients, necessitating regular monitoring. Ocrelizumab, rituximab, and ublituximab are associated with an increased risk of infections (especially respiratory and skin infections), infusion reactions, and hypogammaglobulinemia. Ocrelizumab additionally poses a heightened risk of immune-mediated colitis and breast cancer, and it is contraindicated for patients with active hepatitis B due to the risk of viral reactivation. Ublituximab has been noted to be linked to potential fetal harm. We report the case of a 42-year-old male with relapsing-remitting multiple sclerosis on ocrelizumab who developed persistent fever and shortness of breath, two weeks after his last ocrelizumab dose. Despite antibiotic treatment for suspected pneumonia, his symptoms persisted. A chest CT scan revealed multifocal ground-glass opacities suggestive of organizing pneumonia, likely secondary to ocrelizumab. The patient’s condition improved with high-dose corticosteroids, underscoring the importance of vigilance for extremely rare ocrelizumab-associated pulmonary side effects and the need for prompt, appropriate intervention.
##plugins.themes.bootstrap3.article.details##
multiple sclerosis, drug-induced organizing pneumonia, ocrelizumab, ground glass opacities, steroids
2. Rallabhandi SSH, Keelapandal Ganesh M, Paul V. Ocrelizumab Induced Organizing Pneumonia: A Case Report. In: B54. CASE REPORTS IN ONCOLOGIC TREATMENT-RELATED LUNG DISEASE. American Thoracic Society; 2024:A3863-A3863. doi:10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A3863
3. Aysan N, Köybaşı G, Satıcı C, et al. Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report. Tuberk Toraks. 2023 Mar;71(1):107-111. doi: 10.5578/tt.20239913. PMID: 36912415; PMCID: PMC10795250.
4. Mattina G, Spina G, Gallo M, Migliore A, Adamo G. A Second Case Report of Organizing Pneumonia following Ocrelizumab use in Patient with Multiple Sclerosis. Medical and Research Publications. https://doi.org/10.5281/zenodo.10200370 [https://www.medicalandresearch.com/current_issue/1758 available at 9/7/2024]
5. Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006 Aug;28(2):422-46. doi: 10.1183/09031936.06.00013505. PMID: 16880372.
6. King TE Jr, Lee JS. Cryptogenic Organizing Pneumonia. N Engl J Med. 2022 Mar 17;386(11):1058-1069. doi: 10.1056/NEJMra2116777. PMID: 35294814.
7. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. doi: 10.1164/ajrccm.165.2.ats01. Erratum in: Am J Respir Crit Care Med2002 Aug 1;166(3):426. PMID: 11790668.
8. Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738. Erratum in: Continuum (Minneap Minn). 2019 Aug;25(4):1175. doi: 10.1212/01.CON.0000575052.49943.50. PMID: 31162313.
9. Gloria Sánchez-Contreras. FDA Approves New Drug to Treat Multiple Sclerosis. Published February 20, 2018. [https://www.fda.gov/news-events/comunicados-de-prensa/la-fda-aprueba-nuevo-medicamento-para-tratar-la-esclerosis-multiple available at 7/7/2024]
10. Patel A, Sul J, Gordon ML, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol. 2021 Jun 1;78(6):736-740. doi: 10.1001/jamaneurol.2021.0627. PMID: 33724354; PMCID: PMC7967248.
11. Ciardi MR, Iannetta M, Zingaropoli MA, et al. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis. 2018 Dec 26;6(1):ofy356. doi: 10.1093/ofid/ofy356. PMID: 30697576; PMCID: PMC6343960.
12. Lee A. Ublituximab: First Approval. Drugs. 2023 Apr;83(5):455-459. doi: 10.1007/s40265-023-01854-z. PMID: 36920653.
13. Mian M, Rass C, Hutarew G, et al. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Leuk Lymphoma. 2006 Aug;47(8):1683-5. doi: 10.1080/10428190600612586. PMID: 16966286.
14. Biehn SE, Kirk D, Rivera MP, et al. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol. 2006 Dec;24(4):234-7. doi: 10.1002/hon.799. PMID: 16948177.
15. Law S, Kwak Y, Felner K, Sauthoff H, Hay J, Smith R. Organizing Pneumonia Associated With Rituximab Therapy for Treatment of Lymphoma. Chest. 2012;142(4):483A. doi:10.1378/chest.1390295
16. Cherian S V., Patel D, Machnicki S, et al. Algorithmic Approach to the Diagnosis of Organizing Pneumonia. Chest. 2022;162(1):156-178. doi:10.1016/j.chest.2021.12.659
17. Ko JP, Girvin F, Moore W, Naidich DP. Approach to Peribronchovascular Disease on CT. Semin Ultrasound CT MR. 2019 Jun;40(3):187-199. doi: 10.1053/j.sult.2018.12.002. PMID: 31200868; PMCID: PMC7126938.
18. Biehn SE, Kirk D, Rivera MP, et al. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol. 2006 Dec;24(4):234-7. doi: 10.1002/hon.799. PMID: 16948177.
19. Marquis KM, Hammer MM, Steinbrecher K, Henry TS, Lin CY, Shifren A, Raptis CA. CT Approach to Lung Injury. Radiographics. 2023 Jul;43(7):e220176. doi: 10.1148/rg.220176. PMID: 37289644.
20. Chong WH, Saha B, Ibrahim A, Smith TC. Dyspnea in a 57-Year-Old Man With Recent Viral Illness. Chest. 2021 Jul;160(1):e19-e24. doi: 10.1016/j.chest.2021.01.012. PMID: 34246383.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.